Evidence map›Paper›PMID 32544361›Full record

Trial reportHuman vaccines & immunotherapeutics2020

Immunogenicity of an

Xiao-Juan Yu, Juan Li, Zhi-Jie Lin, Hui Zhao, Bi-Zhen Lin, You-Lin Qiao, Yue-Mei Hu, Li-Hui Wei, Rong-Cheng Li, Wei-Dan Huang and 5 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Immune Responses to Human Papillomavirus After Infection and Vaccination.Current topics in microbiology and immunology · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Xiao-Juan YuThe State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics(SCIBP), School of Public Health, Xiamen University , Xiamen, Fujian, China.
Juan LiDivision of Respiratory Virus Vaccines, National Institute for Food and Drug Control , Beijing, China.
Zhi-Jie LinVaccine R&D Department, Xiamen Innovax Biotech Company , Xiamen, Fujian, China.
Hui ZhaoDivision of Respiratory Virus Vaccines, National Institute for Food and Drug Control , Beijing, China.
Bi-Zhen LinVaccine R&D Department, Xiamen Innovax Biotech Company , Xiamen, Fujian, China.
You-Lin QiaoDepartment of Cancer Epidemiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, China.
Yue-Mei HuDepartment of Vaccine Evaluation, Jiangsu Provincial Center for Disease Control and Prevention , Nanjing, Jiangsu, China.
Li-Hui WeiDepartment of Obstetrics and Gynecology, Peking University People's Hospital , Beijing, China.
Rong-Cheng LiCenter for Vaccine Clinical Research, Guangxi Center for Disease Control and Prevention , Nanning, Guangxi, China.
Wei-Dan HuangVaccine R&D Department, Xiamen Innovax Biotech Company , Xiamen, Fujian, China.
Ting WuThe State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics(SCIBP), School of Public Health, Xiamen University , Xiamen, Fujian, China.
Shou-Jie HuangThe State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics(SCIBP), School of Public Health, Xiamen University , Xiamen, Fujian, China.
Chang-Gui LiDivision of Respiratory Virus Vaccines, National Institute for Food and Drug Control , Beijing, China.
Hui-Rong PanVaccine R&D Department, Xiamen Innovax Biotech Company , Xiamen, Fujian, China.
Jun ZhangThe State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics(SCIBP), School of Public Health, Xiamen University , Xiamen, Fujian, China.
Xiamen University · CNNational Institutes for Food and Drug Control · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNGuangxi Center for Disease Prevention and Control · CNJiangsu Provincial Center for Disease Control and Prevention · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesAdolescentAdultAntibodies, ViralChinaEscherichia coliFemaleHuman papillomavirus 16Human papillomavirus 18HumansImmunogenicity, VaccineMiddle AgedVaccinationYoung AdultAntibodies, ViralPapillomavirus Vaccinesantibody responsebivalentEscherichia coliHuman papillomavirus vaccineimmunogenicityvaccination interval

Identifiers

PMID32544361
PMCPMC7482734
OpenAlexW3034547816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.